These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12516983)

  • 1. Statistical issues in cost-effectiveness analyses.
    Thompson S
    Stat Methods Med Res; 2002 Dec; 11(6):453-4. PubMed ID: 12516983
    [No Abstract]   [Full Text] [Related]  

  • 2. Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'.
    Briggs A; Fenn P
    Health Econ; 1997; 6(5):491-5. PubMed ID: 9353649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of average cost-effective ratios.
    Laska EM; Meisner M; Siegel C
    Health Econ; 1997; 6(5):497-504. PubMed ID: 9353650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.
    O'Brien BJ; Briggs AH
    Stat Methods Med Res; 2002 Dec; 11(6):455-68. PubMed ID: 12516984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definition, interpretation and calculation of cost-effectiveness acceptability curves.
    Löthgren M; Zethraeus N
    Health Econ; 2000 Oct; 9(7):623-30. PubMed ID: 11103928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group.
    Weinstein MC; Siegel JE; Garber AM; Lipscomb J; Luce BR; Manning WG; Torrance GW
    Health Econ; 1997; 6(5):505-10. PubMed ID: 9353651
    [No Abstract]   [Full Text] [Related]  

  • 7. A proposed model for conducting institutional-specific cost-effectiveness analysis: a case study of lipid-lowering agents.
    Hakim Z; Pierson JF; Pathak DS
    Pharm Pract Manag Q; 1996 Apr; 16(1):79-97. PubMed ID: 10157744
    [No Abstract]   [Full Text] [Related]  

  • 8. A comparative application of econometric frontier and DEA methods for assessing cost efficiency of Finnish hospitals.
    Linna M; Häkkinen U
    Dev Health Econ Public Policy; 1998; 6():169-87. PubMed ID: 10662403
    [No Abstract]   [Full Text] [Related]  

  • 9. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care.
    O'Brien BJ; Drummond MF; Labelle RJ; Willan A
    Med Care; 1994 Feb; 32(2):150-63. PubMed ID: 8302107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who's better not best: appropriate probabilistic uncertainty analysis.
    Coyle D
    Int J Technol Assess Health Care; 2003; 19(3):540-5. PubMed ID: 12962341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confidence intervals for cost/effectiveness ratios.
    Wakker P; Klaassen MP
    Health Econ; 1995; 4(5):373-81. PubMed ID: 8563835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis.
    Hoch JS; Briggs AH; Willan AR
    Health Econ; 2002 Jul; 11(5):415-30. PubMed ID: 12112491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?
    O'Hagan A; Stevens JW
    Health Econ; 2003 Jan; 12(1):33-49. PubMed ID: 12483759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forget CEA (cost effectiveness analysis). Use DEA (data envelopment analysis)!
    Rosenberg D
    J Health Hum Resour Adm; 1991; 14(1):109-12. PubMed ID: 10115636
    [No Abstract]   [Full Text] [Related]  

  • 15. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion.
    Brouwer WB; Koopmanschap MA; Rutten FF
    Health Econ; 1997; 6(5):511-4. PubMed ID: 9353652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.
    O'Hagan A; Stevens JW
    Stat Methods Med Res; 2002 Dec; 11(6):469-90. PubMed ID: 12516985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the discounting of gained life-years in cost-effectiveness analysis.
    Johannesson M
    Int J Technol Assess Health Care; 1992; 8(2):359-64. PubMed ID: 1628916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics.
    Bridges JF
    Appl Health Econ Health Policy; 2003; 2(4):213-24. PubMed ID: 15119540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling programme costs in economic evaluation.
    Fenn P; McGuire A; Backhouse M; Jones D
    J Health Econ; 1996 Feb; 15(1):115-25. PubMed ID: 10157425
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.